J.P. Morgan Maintains Overweight on Pfizer

J.P. Morgan is out with its report today on Pfizer PFE, maintaining Overweight. In its report, J.P. Morgan writes, "We believe Pfizer's strategic view has helped refocus the Street on the value of the various business units within Pfizer even though the outcome of the process (seeking alternatives for animal health and nutritionals) did not drastically alter the structure of the company's core pharma franchise." J.P. Morgan maintains a $25 PT on PFE. At the time of posting, shares of PFE were trading at $18.70, up 2.69% from Friday's close.